Attenuated Streptococcus suis vaccines and methods of making and use thereof

Patent metadata

Field	Value
Publication number	US-9289484-B2
Application number	US-201313924871-A
Country	US
Kind code	B2
Filing date	Jun 24, 2013
Priority date	Jun 27, 2012
Publication date	Mar 22, 2016
Grant date	Mar 22, 2016

Abstract

The present invention provides attenuated S. suis strains that elicit an immune response in animals against S. suis, compositions comprising said strains, methods of vaccination against S. suis , and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.

First claim

What is claimed is:

1. An attenuated Streptococcus suis ( S. suis ) vaccine strain capable of providing a safe and protective immune response in porcine against S. suis or diseases caused by S. suis;
wherein the strain comprises one or more virulence gene(s), coding for polypeptide(s) having one or more amino acid substitutions relative to the corresponding polypeptide(s) in the strain's corresponding virulent parental S. suis strain; and
wherein the genes are rpsL-S12 (a 3 oS ribosomal subunit protein), an ABC transporter ATP binding membrane protein (ABC-ATPBMP), marR transcription regulator, or combinations thereof.

2. The vaccine strain of claim 1 , comprising nucleic acid sequences as set forth in SEQ ID NOs:3, 7and 11.

3. The vaccine strain of claim 1 , wherein the level(s) of the peptide(s) expressed by the rpsL-S12, the ABC-ATPBMP, marR, or combinations thereof, is reduced relative to the parent S. suis strain, which expresses rpsL-S12, ABC-ATPBMP, and marR peptides having the sequence as set forth in SEQ ID NOs:2 (rpsL-S12), 6 (ABC-ATPBMP), and 10 (marR).

4. The vaccine strain of claim 1 , characterized in that it comprises nucleic acids sequences having a C in a position corresponding to nucleotide 167 of SEQ ID NO:3; a C in a position corresponding to nucleotide 301 of SEQ ID NO:3; an A in a position corresponding to nucleotide 323 of SEQ ID NO:7; and a T in a position corresponding to nucleotide 265 of SEQ ID NO:11.

5. The vaccine strain of claim 4 , characterized in that it is the strain deposited at the ATCC under the Patent Deposit Designation PTA-13269.

6. A vaccine composition comprising the attenuated vaccine strain of claim 1 , and a pharmaceutically or veterinarily acceptable vehicle, diluent or excipient.

7. The vaccine composition of claim 6 , further comprising an adjuvant.

8. The vaccine composition of claim 7 , wherein the adjuvant is selected from chitosan, methylated chitosan, trimethylated chitosan and combinations thereof.

9. The vaccine composition of claim 8 , wherein the adjuvant is chitosan.

10. The vaccine composition of claim 7 , wherein the adjuvant is inactivated bacteria, inactivated virus, fractions of inactivated bacteria, bacterial lipopolysaccharides, bacterial toxins, or derivatives or combinations thereof.

11. The vaccine composition of claim 10 , further comprising at least one additional antigen.

12. The vaccine composition of claim 11 , wherein the at least one additional antigens is capable of eliciting in a porcine an immune response against M. hyo, PCV2, PRRSV or SIV.

Assignees

• Bey Russell F
• Lawrence Paulraj Kirubakaran
• Simonson Randy R
• Sirigireddy Kamesh Reddy
• Mckeown Danielle A
• Merial Inc

Inventors

• Bey Russell F
• Lawrence Paulraj Kirubakaran
• Simonson Randy R
• Sirigireddy Kamesh Reddy
• Mckeown Danielle A

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C12N1/20 Primary

  Bacteria; Culture media therefor · CPC title